HC Wainwright & Co. Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and raises the price target from $13 to $14.
May 14, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Verrica Pharmaceuticals and raises the price target from $13 to $14, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst suggests a strong belief in the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100